Conditions: Vasovagal Syncope
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 57
Healthy volunteers: no

Brief summary:
Objective: To determine if atomoxetine 40 mg bid (bis in die) in patients ≥18 years old with recurrent vasovagal syncope will better prevent syncope during tilt testing than placebo.

Detailed description:
Background: Syncope affects about 50% of Canadians, is the cause of 1-2% of emergency room visits, and probably is responsible for C$250 million (Canadian dollars) in health care spending each year. It is associated with decreased quality of life, trauma, loss of employment, and limitations in daily activities. The most common cause is vasovagal syncope. This occurs in people of all ages, and is a lifelong predilection. While the median number of faints in the population is 2, those who come to the investigators' care have a median 10-15 lifetime spells, and have an increased frequency in the year before presentation. Vasovagal syncope is due to abrupt hypotension and transient bradycardia, which cause cerebral hypoperfusion. The pathophysiology may be either failure of venous return or progressive vasodilation, both due to inappropriately low sympathetic outflow.

There is no known medical treatment for frequent fainting. The investigators performed the pivotal Canadian Institutes of Health Research (CIHR)-funded randomized trials that showed that neither permanent pacing, beta blockers, nor fludrocortisone help the majority of patients. However 2 randomized studies suggest that inhibition of norepinephrine transport (NET) reuptake with sibutramine and reboxetine (NET inhibitors) prevents syncope on tilt testing by about 80%, and the investigators reported that sibutramine markedly reduced the frequency of vasovagal syncope in 7 of our most symptomatic patients. Sibutramine and reboxetine, for different reasons, are not available in Canada. However atomoxetine is available and is used to help patients with attention deficit disorder. There are no data pertaining to its hemodynamic effects in patients with vasovagal syncope. Although a randomized clinical trial of atomoxetine for the prevention of vasovagal syncope would be needed before clinical use, a proof of principle study is needed first.

Objective: To determine if atomoxetine 40 mg bid (bis in die) in patients ≥18 years old with recurrent vasovagal syncope will better prevent syncope during tilt testing than placebo.

Methods: The investigators will conduct a prospective, randomized, parallel, double-blind, proof-of-concept study to test the hypothesis that norepinephrine transporter inhibition with Atomoxetine prevents tilt-induced vasovagal syncope (VVS)/pre-syncope in patients with clinical vasovagal syncope. Subjects will have had ≥1 faint in the previous year, and a diagnosis of vasovagal syncope based on the Calgary Syncope Symptom Score. The primary outcome measure will be the time to syncope or presyncope with a trough rate-pressure product \<7000 mm Hg/min. The primary analysis will be performed on an intention-to-treat basis. Secondary analyses will include modelled estimations of systemic vascular resistance and stroke volume, based on arterial waveform and blood pressure. This will permit us to address whether NET inhibition prevents the vasovagal reflex by maintenance of cardiac preload or maintenance of systemic vascular resistance. The investigators will randomize 64 patients in a double blind acute phase 2 study to either Atomoxetine 40mg PO bid x 2 doses or matching placebo.

A sample size of 56 syncope patients would have 85% power to detect a 60% relative risk reduction from a placebo outcome rate of 65%, using an unmatched 2-tailed test with alpha=0.05. To compensate for the report dropout rate we will inflate the sample by 15% to 64 subjects. A formal, blinded mid-way safety and efficacy analysis will be performed with a p\<0.01 stopping rule for efficacy. The sample size will be inflated to 74 to account for spending power on the interim analysis. This will provide 85% power to detect an 80% relative risk reduction.

Relevance: This will be the first adequately powered study of the ability of atomoxetine to prevent the vasovagal reflex. It will also provide insight as to whether norepinephrine transport inhibition functions here to maintain venous return or increase systemic vascular resistance. If positive, the study will provide a strong biomedical rationale and preliminary clinical results leading to a randomized clinical trial of atomoxetine for the prevention of vasovagal syncope.

Arms:
arm 1: Placebo capsule to be given the night before the study tilt, and the morning of the study tilt test. arm 2: Atomoxetine 40mg PO to be given the night before the study tilt, and the morning of the study tilt test.

Interventions: intervention 1: Atomoxetine intervention 2: Placebo
Intervention descriptions: intervention 1: 40mg PO the night before and the morning of the study tilt table test. intervention 2: oral placebo capsule designed to blind the atomoxetine intervention

Protocol document:
Prot_SAP_000.pdf: 
A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
1 
I.  OVERVIEW 
About 20% of adults faint recurrently.  These patients are often highly symptomatic, 
have problems with employment and driving, and have reduced quality of life. There are no 
therapies that have withstood the test of adequately designed and conducted randomized 
clinical trials. We will conduct a prospective, randomized, parallel, double-blind, proof-of-
concept study to test the hypothesis that norepinephrine transporter inhibition (with 
atomoxetine) prevents tilt-induced vasovagal syncope (VVS)/pre-syncope in patients with 
clinical VVS. A total of 64 patients with quantitative clinical diagnostic criteria for VVS and 
at least 1 syncopal spell in the preceding year will be randomized in a double blind acute 
phase 2 study to atomoxetine 40mg PO BID x 2 doses or matching placebo.  The endpoint 
will be the onset of presyncope or syncope on tilt testing associated with diagnostic 
hemodynamic changes. These data should provide useful preliminary data as a foundation 
on which to conduct a subsequent randomized clinical trial.   
 
II. BACKGROUND 
2.1. Syncope Natural History: VVS is a common and frequently distressing 
problem.  About 40% of people faint at least once in their life, and at least 20% of adults 
faint more than once1, 2. It usually first presents in adolescence and early adulthood, and 
the predilection to fainting is lifelong. 1-4 Most patients seen in referral clinics have fainted 
repeatedly; in the University of Calgary Syncope Clinic, the median number of faints is 10-
15, over a median duration of 15-20 years. In the 1st and 2nd Prevention of Syncope Trials 
(POST 5 and POST2 6) the median number of syncopal spells in the preceding year was 4. 
Many patients have frequent presyncopal spells. Although most syncope patients do not 
require lifetime therapy, some do merit treatment that lasts from months to years. 
2.2. Syncope Severity and Quality of Life: VVS carries a surprisingly high clinical 
burden. About 18% of syncope patients have trauma associated with syncope ranging from 
bruises through fractures to head injuries. Patients with frequent syncope have a markedly 
reduced quality of life, similar to that of patients with severe rheumatoid arthritis or 
chronic low back pain7-9. Patients with syncope have a reduced quality of life that is related 
to the frequency of syncope. Quality of life is substantially impaired in all dimensions of 
health, and particularly in terms of mobility, usual activities, and self care7-9.  
2.3. Impact on Health Care System: Most patients with syncope with otherwise 
unknown cause in the community, and about 43% of syncope patients who present to 
emergency rooms in North American and Europe have VVS.  In the United States about $2.4 
billion is spent yearly in hospitals caring for patients with syncope10. In the Netherlands 
population 0-65 years old there are 3.8 and 8.5 visits for syncope per 1000 person years to 
family doctors for males and females, respectively3. In Canada we estimate about 418,000 
visits yearly to family physicians for syncope, and about 39,000 to 100,000 visits yearly to 
the emergency room, for a total of at least 457,000 visits for care of syncope annually.  
2.4. Current Treatments: VVS is characterized by paroxysmal, reflex-mediated 
hypotension and bradycardia. Serotonin, opiate, and beta-adrenergic receptors might 
mediate integration of this reflex response.  Bradycardia is caused by increased vagal tone 
and hypotension is caused by withdrawal of alpha-adrenergic tone to venous and 
resistance vessels.  


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
2 
2.4.1. Diet and physical manoeuvres: Many syncope patients are encouraged to 
increase their salt and fluid intake, although the evidence is weak and comes mainly from 
tilt test studies11. The usual reported dose of salt tablets is 6-9 gm (100-150 mmol) per day. 
There is limited evidence supporting the use of exercise training to prevent syncope 12, but 
a very underpowered randomized study did not detect a reduction in the likelihood of 
syncope in exercised patients13.  Considerable evidence supports the use of physical 
counterpressure manoeuvres (PCM), which are squats or isometric contractions of the legs. 
The Physical Counterpressure Manoeuvres Trial (PC Trial) was a randomized controlled 
trial that showed some benefit compared to conventional therapy 14. However, fully 35% of 
patients had insufficient prodrome to perform the techniques, and the effect size in the PC 
Trial is about the same as the placebo effect size in general.  
2.4.2. Beta blockers: There have been 5 randomized clinical trials of the efficacy or 
effectiveness of b-adrenergic blockers for the prevention of syncope15.  On the whole they 
were negative. We reported the results of POST in 20065. It was the pivotal randomized, 
placebo-controlled, double-blind trial, and assessed the effects of metoprolol in VVS over a 
1 year treatment period. A total of 208 patients were randomized to metoprolol or placebo.  
Metoprolol provided no benefit, with nearly identical outcome rates in both study arms. 
More recently, we reported a small meta-analysis that showed a 50% risk reduction with 
beta blockers in patients >42 years old. 
2.4.3. Fludrocortisone: Fludrocortisone is a corticosteroid with mainly 
mineralocorticoid activity resulting in sodium and water retention and potassium 
excretion, which should increase blood volume. To assess its effectiveness in adults we 
conducted POST2), a multinational, randomized, placebo-controlled clinical trial6. A total of 
209 patients with recurrent VVS received either fludrocortisone or placebo for 1 year; the 
primary outcome is the proportion of patients with at least one syncope recurrence. There 
was only a trend to benefit, with a 30% relative risk reduction (p=0.07) 
2.4.4. Serotonin reuptake inhibitors: Central serotonin levels might contribute to VVS.  
A randomized, double blind, placebo-controlled study of 68 consecutive patients who had 
not responded to other treatments was reported to be positive16 but this could not be 
reproduced in two further studies 17. 18  
2.4.5. Permanent pacemakers: Permanent pacemakers do not benefit the majority of 
patients with VVS, although those over 40 years of age with documented asystolic pauses 
during syncope do benefit from pacing. The strategy of first screening with an implanted 
loop recorder, then inserting a permanent pacemaker if indicated, will only benefit 3-10% 
of older patients.  
2.4.6. Midodrine is a pro-drug whose active metabolite is effective in preventing 
orthostatic hypotension secondary to autonomic failure. Midodrine prevents 
orthostatic hypotension in patients with autonomic failure19, 20. Whether it is effective 
in VVS is not established conclusively. It was beneficial in 4 small and inadequately 
designed clinical trials21 22 23, and is now the subject of the POST 4: Assessment of 
Midodrine in the Prevention of Vasovagal Syncope 24. 
2.5. Norepinephrine and VVS: Numerous early studies suggested that the 
hypotension accompanying VVS is due to an abrupt withdrawal of sympathetic traffic, 
resulting in vasodilatation and a reduction in peripheral resistance25-27. However this has 
been challenged repeatedly 28-30. We reported a failure of venoconstriction during mental 
stress in syncope patients but not control subjects 31, and two groups have recently 


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
3 
reported that the principle hemodynamic change leading up to presyncope on tilt tests is 
peripheral venous pooling and a reduction in cardiac output in the face of unchanged 
peripheral resistance, implying a reduction in venous return32, 33. Therefore the 
hypotension of VVS might be due to a failure of venoconstriction, vasoconstriction, or both. 
We will address this as a substudy of this proposed phase 2 trial.  
2.6.1. Norepinephrine Transporter Dysregulation in VVS: Norepinephrine 
released at central and peripheral synapses is inactivated through active transport into 
terminals by the presynaptically-localized norepinephrine transporter (NET).35 NET 
immunoreactivity is present in sympathetic nerves and central nervous system 
noradrenergic neurons near NE release sites34, 35. NET recaptures as much as 90% of 
released norepinephrine in the heart, making it a critical mediator of NE inactivation and 
presynaptic catecholamine homeostasis36. NET is also a target for tricyclic antidepressants, 
NET-selective reuptake inhibitors (NRIs; common antidepressants), and 
psychostimulants37, 38. The importance of NET to norepinephrine homeostasis suggests that 
NET dysfunction may contribute to the autonomic reflexes causing VVS. 
Central to this proposal is the growing evidence that NET dysregulation is 
present in VVS. Vaddadi et al. 30 have recently reported on their study of sympathetic 
nervous system responses to head up tilt test in VVS compared to healthy controls. Healthy 
subjects increased both their muscle sympathetic nerve activity (MSNA) and their 
norepinephrine spillover to plasma with tilt. The VVS patients also increased their MSNA to 
a similar or greater degree, but the NE spillover response was subnormal. Thus, VVS 
patients exhibited disconnect between nerve firing and norepinephrine release, 
lowering norepinephrine availability, and impairing the circulatory response with resultant 
syncope. These data suggest that there are some VVS patients with excessive 
norepinephrine reuptake (and thus excessive norepinephrine clearance) from the 
sympathetic nerve terminal, which in turn results in inadequate vasoconstriction and 
clinical syncope in response to orthostatic stress. These VVS patients may benefit from a 
reduction in their NET activity with pharmacological NET inhibitors. 
2.6.2. NET Inhibition with Atomoxetine Raises Blood Pressure in Patients with 
Central Autonomic Failure: Atomoxetine 18mg (pediatric dose) and placebo, in a 
crossover fashion, to 10 patients with central autonomic failure and clinical orthostatic 
hypotension with syncope39. At 1 hour, atomoxetine acutely increased seated and standing 
systolic BP in patients with central autonomic failure by 54±26 mmHg (mean±SD; P=0.004) 
and 45±23 mmHg (P=0.016), respectively, as compared with placebo. This increase in BP is 
likely due to an increase in vasoconstriction and venoconstriction. While one might not 
expect such a striking increase in BP in VVS patients (given their intact autonomic reflexes), 
these data provide “proof of concept” that NET inhibition can support BP and HR in 
patients with syncope disorders. 
2.6.3. NET Inhibition to Prevent Tilt-Induced Syncope in Healthy Volunteers: 
Reboxetine is a highly specific norepinephrine transporter inhibitor approved as a clinical 
antidepressant in Europe, but not in the North America. Its high specificity as a NET 
inhibitor led Schroeder et al40 to question whether high doses might transiently induce a 
clinical state resembling postural tachycardia syndrome (POTS). They gave 18 healthy 
volunteers reboxetine 8 mg orally 12 hours and 1 hour before observations, and compared 
their responses to reboxetine vs. placebo. As part of the study the subjects underwent 
prolonged head-up tilt table testing, a major diagnostic modality for VVS. Of the 18 subjects, 


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
4 
9 fainted while taking placebo and only 1 fainted while taking reboxetine (P<0.01). This 
was reproduced in further studies using reboxetine and another NET inhibitor, 
sibutramine41. The mechanism of benefit of NET inhibition in VVS is unclear: it might be 
simply acting indirectly as a peripheral arterial vasoconstrictor, a peripheral 
venoconstrictor, or through another novel mechanism. NET inhibitors are the only drug 
class in credible, placebo-controlled studies to show efficacy in preventing syncope induced 
by tilt table testing.  
2.6.4. NET Inhibition to Decrease Faints in Malignant VVS: Sibutramine was an 
anorexigenic agent that was widely available in North America and Europe before the 
results of the SCOUT trial were released42. While it was available we performed an 
observational, compassionate use, off-label, prospective dose-ranging study of sibutramine 
in the suppression of VVS in extremely symptomatic patients43. Seven patients with very 
frequent and medically-refractory syncope were treated with 10 mg/day, 15 mg/day and 
20 mg/day sibutramine for 1 month each.  All doses were tolerated by 6 patients (83%). 
The median spell frequency (per 28 days) decreased from 8 (no sibutramine) to 4 
(10mg/day), to 3 (15mg/day) and to 1 (20 mg/day). Five patients were “responders” to 
sibutramine, pre-specified as >50% reduction in spells at the maximal tolerated dose. 
These data suggest that NET inhibition can be effective in preventing VVS in highly 
symptomatic patients.   
2.6.5. Drug availability. Sibutramine was withdrawn from the market after the 
SCOUT study results were released, and reboxetine, although available in Europe, did not 
have a successful pivotal study for depression in North America. Pfizer refused to make it 
available for further study. Atomoxetine39 is clinically approved in Canada and the United 
States of America for treatment of attention deficit disorder44. 
 
 
III. PROPOSED STUDY 
3.1. Hypothesis: We will test the hypothesis that pharmacological NET inhibition 
will increase tilt test tolerance prior to syncope in patients with recurrent VVS. 
3.3. Inclusion criteria: Patients will be eligible if they have: (A) ≥1 syncopal spells 
in the year preceding enrolment, and (B) ≥-2 points on the Calgary Syncope Symptom Score, 
and (C) Age ≥18 years with informed consent. The Calgary Syncope Symptom Score is used 
to diagnose VVS in patients with structurally normal hearts45. It has an overall 90% 
accuracy in distinguishing VVS from other causes of syncope in this population. It provided 
the diagnostic inclusion criteria for POST2 (a randomized clinical trial of fludrocortisone6, 
and for a study of the impact of a parental history of fainting on the likelihood of fainting in 
offspring2 and is used in POST4 and POST5. It will provide inclusion criteria for this study  
3.4. Exclusion criteria: Patients will be excluded if they have: (1) other causes of 
syncope, such as ventricular tachycardia, complete heart block, orthostatic hypotension or 
hypersensitive carotid sinus syndrome, (2) an inability to give informed consent, (3) 
important valvular, coronary, myocardial or conduction abnormality or significant 
arrhythmia, (4) hypertrophic cardiomyopathy, (5) a permanent pacemaker, (6) a seizure 
disorder, (7) hypertension defined as >150/90 mm Hg (8) pregnancy, (9) lactating women, 
(10) glaucoma, (11) medications with known effects on blood pressure, (12) Known 


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
5 
hypersensitivity to atomoxetine and derivatives, and (13) other factors which, in the 
investigator’s opinion, would prevent the subject from completing the protocol. 
3.5. Enrollment/recruitment: Patients will be recruited locally from referrals to 
the University of Calgary Syncope Clinic. Patients will also be recruited at Vanderbilt 
University and McMaster University. Studies in Calgary will take place in the Libin 
Cardiovascular Institute of Alberta. 
3.6. Screening: Each subject will have undergone a complete history and physical 
examination with an electrocardiogram (ECG) has not been performed in the previous 5 
years, one will be done as part of routine practice. 
3.7. Study Diet and Co-Medications: Subjects will be asked to avoid or discontinue 
all non-prescription medications and supplements that might contain stimulants on the day 
before the study.   
3.8. Study Design: This will be a randomized, double-blind, parallel-arm study in 
which the subjects will undergo a tilt table test following 2 doses of atomoxetine 40mg PO 
(evening before and morning of study) or after 2 doses of matching placebo (on separate 
days). On the morning of the study, the fasting subject (except for medications) will be 
instrumented, on an empty bladder. ECG electrodes will be applied to monitor continuous 
heart rhythm. Blood pressure will be monitored continuously using a finger volume clamp 
method using one or more of several extant devices, and calibrated with intermittent 
brachial cuff measurements. One intravenous cannula will be placed in the contralateral 
arm (to the blood pressure cuff) for blood sampling. 
3.9. Tilt Table Protocol: Following the insertion of the venous cannulae, a period of 
at least 20 minutes will be allowed to elapse before a 10-minute basal control (baseline) 
period.  Baseline data will be digitally recorded in this time. In the last 5 minutes of this 
period, blood will be drawn for fractionated plasma catecholamines. The table will be 
rapidly raised to 80 degrees for up to 60 minutes. We are deliberately avoiding tilt test 
methods with provocative medications to avoid the issue of multiple causal factors. At 10 
minutes and 30 minutes following onset of tilt (or at the onset of severe presyncope or 
hypotension [systolic blood pressure <70 mmHg]), venous fractionated catecholamines 
will be sampled. The study will be terminated if the subject develops syncope, at the 
completion of the protocol, or if the subject requests termination.  
3.10 Questionnaires: A brief online questionnaire will be administered to the 
patients to get a metric of their health-related quality of life (RAND-36), anxiety and 
depression symptoms (HADS), orthostatic symptom burden (OGS) and global ratings of 
fatigue and well-being. This will be administered through RedCap Survey through the 
University of Calgary. 
3.11. Trial Team: The Principal Investigators will be Drs RS Sheldon (Calgary), Dr C 
Morillo (McMaster) and Dr SR Raj (Calgary). Coordination, data management, and analysis 
will be performed in Calgary.  
 
IV. STATISTICAL CONSIDERATIONS 
4.1. Primary Analysis: The primary statistical analysis will assess whether 
atomoxetine, compared to placebo, reduces the proportion of subjects who become 
presyncopal or syncopal associated with diagnostic criteria of hypotension and 
bradycardia. A Chi Square test will assess the statistical significance of the difference in 


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
6 
outcome proportions.  The results will be displayed in a Kaplan-Meier analysis and the 
significance of differences between the two arms of the study tested with the log-rank test. 
4.2. Secondary Analyses: Secondary non-clinical endpoints will include plasma 
catecholamine levels, changes in estimated stroke volume (from the continuous BP 
monitor), cardiac output, and systematic vascular resistance. These will all be compared 
between the two interventions. 
4.3. General Statistical Considerations: Parametric data will be presented as 
mean±SD, and non-parametric data with median and interquartile range.  Paired data will 
be analysed using an unpaired t-test for parametric data, or a Wilcoxon signed-rank test 
used for non-parametric analysis. Confidence intervals (95%) will be reported when 
appropriate.  All analytical techniques will be two-sided.  Exact P values will be reported.   
Data will be entered into a Microsoft Excel spreadsheet or a REDCap database and SPSS for 
Windows (version 21.0) or similar statistical software package will be used for data 
analysis.   
4.4. Sample Size Calculation: Sample size was calculated based upon the primary 
clinical endpoint. In a review of 4 studies comprising 304 patients utilizing this tilt test 
protocol (at 60 degree head-up tilt) the likelihood of a positive test was 69%. Locally we 
conducted a randomized trial of the tilt angles 60 degrees versus 80 degrees 46. The 
likelihood of a positive tilt test outcome was 0.6% and 1.1% per minute at 60 and 80 
degrees. Therefore after 60 minutes of 80 degree head-up tilt we expect a positivity rate of 
65%. The effect of NET inhibitors used a slightly different tilt test protocol, and the positive 
outcome rate was 49% in the placebo arms. In the NET intervention arms the positive 
outcome rate was 18%, of which 4% was due to diagnostic presyncope and 14% was due to 
orthostatic intolerance without bradycardia or hypotension.  The corresponding relative 
risks were 37% and 8%.  The latter is equivalent to a 92% relative risk reduction, which 
seems higher than may be clinically expected. A sample size of 56 syncope patients will 
have 85% power to detect a 60% relative risk reduction from a placebo outcome rate of 
65%, using an unmatched 2-tailed test with alpha=0.05. To compensate for the report 
dropout rate we will inflate the sample by 15% to 64 subjects. A formal, blinded mid-way 
safety and efficacy analysis will be performed with a p<0.01 stopping rule for efficacy. This 
also will provide 85% power to detect an 80% relative risk reduction. 
4.5. Randomization: Randomization will be carried out using a computerized 
algorithm. Patients will be randomized in a double-blind fashion to receive atomoxetine 
40mg PO x2 or matching placebo with a 1:1 randomization ratio. Medication containers 
will be centrally filled and labeled with the randomization code number. 
 
V. ADVERSE EVENTS AND INCONVENIENCES 
5.1 Event types will be listed in the informed consent form.  
Study Diet: If you regularly drink caffeine, you may have a headache or be irritable from not 
drinking caffeine on the day of the study. 
IV Cannulation: Having tubes put in your veins may be painful and may cause bleeding, 
bruising, or rarely infection. 
Drawing blood may cause discomfort or bruising 
The sticky patches on your skin may itch or cause a reaction. 


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
7 
Blood Pressure Measurement; The blood pressure measurements may be painful, or rarely 
cause bruising, numbness and tingling in the fingers. There will also be a short *time of 
poor blood flow in the arm/hand that is being cuffed during the measurements. 
Tilt Table Test: There might be lightheadedness, dizziness, tremor, headache, nausea or 
fainting during the tilt table test. These symptoms usually resolve rapidly upon lowering of 
the table. 
5.1 Adverse Event (or Unanticipated Problem) Reporting: Any adverse events of 
a serious nature will be reviewed immediately with the principal investigator.  Serious 
adverse events will be reported in writing to the University of Calgary IRB, within 10 
business days of the research team’s first knowledge of the occurrence. Robert Sheldon MD 
PhD will be responsible for tracking adverse events in this study. The adverse event will be 
described with the following information:  description of the event, outcome of the event, 
how long it lasted, relationship to study medications, whether the event required treatment 
or intervention, and the outcome. 
The definition of events is as follows: 
• Mild – transient and mild in nature, with no treatment necessary. 
• Moderate – some intervention and treatment necessary, but subject completely 
recovers. 
• Severe – an event that results in hospitalization, disability, death or is life threatening. 
The investigator will state his opinion as to whether there is a reasonable possibility 
that the event or experience is related to the drug. 
 
VI. SUMMARY AND IMPLICATIONS 
This will be the first adequately powered study of the ability of atomoxetine to 
prevent the vasovagal reflex. It will also provide insight as to whether norepinephrine 
transport inhibition functions here to maintain venous return or increase systemic vascular 
resistance. If positive, the study will provide a strong biomedical rationale and preliminary 
clinical results leading to POST 7: a randomized clinical trial of atomoxetine for the 
prevention of vasovagal syncope. 
 
 
 
 
 


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
8 
REFERENCES 
 
1. 
Ganzeboom KS, Mairuhu G, Reitsma JB, Linzer M, Wieling W, van Dijk N. Lifetime 
cumulative incidence of syncope in the general population: a study of 549 Dutch subjects 
aged 35-60 years. J Cardiovasc Electrophysiol. 2006;17(11):1172-1176. 
2. 
Serletis A, Rose S, Sheldon AG, Sheldon RS. Vasovagal syncope in medical students and 
their first-degree relatives. Eur Heart J. 2006;27(16):1965-1970. 
3. 
Olde Nordkamp LR, van Dijk N, Ganzeboom KS, Reitsma JB, Luitse JS, Dekker LR, Shen 
WK, Wieling W. Syncope prevalence in the ED compared to general practice and 
population: a strong selection process. Am J Emerg Med. 2009;27(3):271-279. 
4. 
Sheldon RS, Sheldon AG, Connolly SJ, Morillo CA, Klingenheben T, Krahn AD, 
Koshman ML, Ritchie D. Age of first faint in patients with vasovagal syncope. J 
Cardiovasc Electrophysiol. 2006;17(1):49-54. 
5. 
Sheldon R, Connolly S, Rose S, Klingenheben T, Krahn A, Morillo C, Talajic M, Ku T, 
Fouad-Tarazi F, Ritchie D, Koshman ML. Prevention of Syncope Trial (POST): a 
randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. 
Circulation. 2006;113(9):1164-1170. 
6. 
Raj SR, Rose S, Ritchie D, Sheldon RS. The Second Prevention of Syncope Trial (POST 
II)--a randomized clinical trial of fludrocortisone for the prevention of neurally mediated 
syncope: rationale and study design. Am Heart J. 2006;151(6):1186.e11-1186.e17. 
7. 
Linzer M, Gold DT, Pontinen M, Divine GW, Felder A, Brooks WB. Recurrent syncope as 
a chronic disease: preliminary validation of a disease-specific measure of functional 
impairment. J Gen Intern Med. 1994;9(4):181-186. 
8. 
Rose MS, Koshman ML, Ritchie D, Sheldon R. The development and preliminary 
validation of a scale measuring the impact of syncope on quality of life. Europace. 
2009;11(10):1369-1374. 
9. 
Rose MS, Koshman ML, Spreng S, Sheldon R. The relationship between health-related 
quality of life and frequency of spells in patients with syncope. J Clin Epidemiol. 
2000;53(12):1209-1216. 
10. Sun BC, Emond JA, Camargo CAJ. Direct medical costs of syncope-related 
hospitalizations in the United States. Am J Cardiol. 2005;95(5):668-671. 
11. Claydon VE, Hainsworth R. Salt supplementation improves orthostatic cerebral and 
peripheral vascular control in patients with syncope. Hypertension. 2004;43(4):809-813. 
12. Mtinangi BL, Hainsworth R. Increased orthostatic tolerance following moderate exercise 
training in patients with unexplained syncope. Heart. 1998;80(6):596-600. 


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
9 
13. Gardenghi G, Rondon MU, Braga AM, Scanavacca MI, Negrao CE, Sosa E, Hachul DT. 
The effects of exercise training on arterial baroreflex sensitivity in neurally mediated 
syncope patients. Eur Heart J. 2007;28(22):2749-2755. 
14. van Dijk N, Quartieri F, Blanc JJ, Garcia-Civera R, Brignole M, Moya A, Wieling W. 
Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the 
Physical Counterpressure Manoeuvres Trial (PC-Trial). J Am Coll Cardiol. 
2006;48(8):1652-1657. 
15. Kuriachan V, Sheldon RS, Platonov M. Evidence-based treatment for vasovagal syncope. 
Heart Rhythm. 2008;5(11):1609-1614. 
16. Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects of 
paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal 
syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 
1999;33(5):1227-1230. 
17. Flevari P, Livanis EG, Theodorakis GN, Zarvalis E, Mesiskli T, Kremastinos DT. 
Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of 
propranolol, nadolol and placebo on syncope recurrence and patients' well-being. J Am Coll 
Cardiol. 2002;40(3):499-504. 
18. Takata TS, Wasmund SL, Smith ML, Li JM, Joglar JA, Banks K, Kowal RC, Page RL, 
Hamdan MH. Serotonin Reuptake Inhibitor (Paxil) Does Not Prevent the Vasovagal 
Reaction Associated With Carotid Sinus Massage and/or Lower Body Negative Pressure in 
Healthy Volunteers. Circulation. 2002;106(12):1500-1504. 
19. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-
Tarazi FM. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study 
with midodrine. Am J Med. 1993;95(1):38-48. 
20. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs 
placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter 
study. Midodrine Study Group. JAMA. 1997;277(13):1046-1051. 
21. Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: a 
double-blind, randomized, crossover study. Ann Neurol. 2002;52(3):342-345. 
22. Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of 
neurocardiogenic syncope. Heart. 1998;79(1):45-49. 
23. Perez-Lugones A, Schweikert R, Pavia S, Sra J, Akhtar M, Jaeger F, Tomassoni GF, Saliba 
W, Leonelli FM, Bash D, Beheiry S, Shewchik J, Tchou PJ, Natale A. Usefulness of 
midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized 
control study. J Cardiovasc Electrophysiol. 2001;12(8):935-938. 
24. Raj SR, Faris PD, McRae M, Sheldon RS. Rationale for the prevention of syncope trial IV: 
assessment of midodrine. Clin Auton Res. 2012;22(6):275-280. 


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
10 
25. Morillo CA, Eckberg DL, Ellenbogen KA, Beightol LA, Hoag JB, Tahvanainen KU, 
Kuusela TA, Diedrich AM. Vagal and sympathetic mechanisms in patients with orthostatic 
vasovagal syncope. Circulation. 1997;96(8):2509-2513. 
26. Mosqueda-Garcia R, Furlan R, Fernandez-Violante R, Desai T, Snell M, Jarai Z, 
Ananthram V, Robertson RM, Robertson D. Sympathetic and baroreceptor reflex function 
in neurally mediated syncope evoked by tilt. J Clin Invest. 1997;99(11):2736-2744. 
27. Mosqueda-Garcia R, Furlan R, Tank J, Fernandez-Violante R. The elusive pathophysiology 
of neurally mediated syncope. Circulation. 2000;102(23):2898-2906. 
28. Dietz NM, Halliwill JR, Spielmann JM, Lawler LA, Papouchado BG, Eickhoff TJ, Joyner 
MJ. Sympathetic withdrawal and forearm vasodilation during vasovagal syncope in 
humans. J Appl Physiol. 1997;82(6):1785-1793. 
29. Dietz NM, Joyner MJ, Shepherd JT. Vasovagal syncope and skeletal muscle vasodilatation: 
the continuing conundrum. Pacing Clin Electrophysiol. 1997;20(3 Pt 2):775-780. 
30. Vaddadi G, Esler MD, Dawood T, Lambert E. Persistence of muscle sympathetic nerve 
activity during vasovagal syncope. Eur Heart J. 2010;31(16):2027-2033. 
31. Manyari DE, Rose S, Tyberg JV, Sheldon RS. Abnormal reflex venous function in patients 
with neuromediated syncope. J Am Coll Cardiol. 1996;27(7):1730-1735. 
32. Stewart JM, McLeod KJ, Sanyal S, Herzberg G, Montgomery LD. Relation of postural 
vasovagal syncope to splanchnic hypervolemia in adolescents. Circulation. 
2004;110(17):2575-2581. 
33. Verheyden B, Liu J, van Dijk N, Westerhof BE, Reybrouck T, Aubert AE, Wieling W. 
Steep fall in cardiac output is main determinant of hypotension during drug-free and 
nitroglycerine-induced orthostatic vasovagal syncope. Heart Rhythm. 2008;5(12):1695-
1701. 
34. Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD. 
Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine 
transporter. J Comp Neurol. 2000;420(2):211-232. 
35. Matthies HJ, Han Q, Shields A, Wright J, Moore JL, Winder DG, Galli A, Blakely RD. 
Subcellular localization of the antidepressant-sensitive norepinephrine transporter. BMC 
Neurosci. 2009;10:65. 
36. Schomig E, Fischer P, Schonfeld CL, Trendelenburg U. The extent of neuronal re-uptake 
of 3H-noradrenaline in isolated vasa deferentia and atria of the rat. Naunyn Schmiedebergs 
Arch Pharmacol. 1989;340(5):502-508. 
37. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of 
antidepressants and related compounds at human monoamine transporters. Eur J 
Pharmacol. 1997;340(2-3):249-258. 


A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope: POST 6 
Version 3; December 20 2015 
11 
38. Fuller RW, Hemrick-Luecke SK. Antagonism by tomoxetine of the depletion of 
norepinephrine and epinephrine in rat brain by alpha-methyl-m-tyrosine. Res Commun 
Chem Pathol Pharmacol. 1983;41(1):169-172. 
39. Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, Robertson D, Biaggioni I. 
Norepinephrine transporter blockade with atomoxetine induces hypertension in patients 
with impaired autonomic function. Hypertension. 2007;50(1):47-53. 
40. Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, Luft FC, 
Jordan J. Selective norepinephrine reuptake inhibition as a human model of orthostatic 
intolerance. Circulation. 2002;105(3):347-353. 
41. Schroeder C, Birkenfeld AL, Mayer AF, Tank J, Diedrich A, Luft FC, Jordan J. 
Norepinephrine transporter inhibition prevents tilt-induced pre-syncope. J Am Coll Cardiol. 
2006;48(3):516-522. 
42. Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma 
AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP. Maintained 
intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine 
Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6):523-530. 
43. Sheldon RS, Ritchie D, McRae M, Raj S. Norepinephrine transport inhibition for treatment 
of vasovagal syncope. J Cardiovasc Electrophysiol. 2013;24(7):799-803. 
44. Cunill R, Castells X, Tobias A, Capella D. Atomoxetine for attention deficit hyperactivity 
disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiol Drug 
Saf. 2013 
45. Sheldon R, Rose S, Connolly S, Ritchie D, Koshman ML, Frenneaux M. Diagnostic criteria 
for vasovagal syncope based on a quantitative history. Eur Heart J. 2006;27(3):344-350. 
46. Sheldon R, Koshman ML. A randomized study of tilt test angle in patients with 
undiagnosed syncope. Can J Cardiol. 2001;17(10):1051-1057.